Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03730012
Title A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Astellas Pharma Global Development, Inc.
Indications

acute myeloid leukemia

Therapies

Atezolizumab + Gilteritinib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Ronald Reagan UCLA Medical Center Los Angeles California 90095 United States Details
University of Chicago Chicago Illinois 60037 United States Details
Northwestern University Chicago Illinois 60611 United States Details
University of Kentucky Lexington Kentucky 40536 United States Details
Roswell Park Cancer Institute (RPCI) Buffalo New York 14263 United States Details
Columbia University Medical Center New York New York 10032 United States Details
Weill Cornell Medical College New York New York 10065 United States Details
The Ohio State University Comprehensive Cancer Center (OSUCCC) Columbus Ohio 43210 United States Details
Vanderbilt Ingram Cancer Center Nashville Tennessee 37232 United States Details
Simmons Comprehensive Cancer Center Dallas Texas 75390 United States Details
University of Texas MD Anderson Houston Texas 77030 United States Details
Medical College of Wisconsin Milwaukee Wisconsin 53226 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field